Immunovant, Inc. is focused on developing innovative therapies for autoimmune diseases by leveraging a patient-centered approach. The company’s pipeline includes several promising candidates targeting various autoimmune conditions, such as Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Thyroid Eye Disease (TED), and Graves’ Disease. Their lead product, IMVT-1402, is currently in preclinical development, while Batoclimab is undergoing advanced clinical trials, including a Phase 3 study for MG and Phase 2 studies for CIDP and TED. This strategic focus on specific therapeutic areas highlights Immunovant's commitment to addressing the complex and diverse needs of patients suffering from these debilitating conditions.

The technologies employed by Immunovant revolve around the modulation of the neonatal Fc receptor (FcRn), which plays a crucial role in regulating antibody levels in the body. By targeting FcRn, Immunovant aims to enhance the therapeutic efficacy of its treatments while minimizing side effects. This approach is particularly relevant for autoimmune diseases, where the immune system mistakenly attacks the body’s own tissues. The company’s research and development efforts are designed to provide tailored solutions that can improve the quality of life for patients with autoimmune disorders, reflecting their vision of enabling normal lives for those affected.

United States

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.

For U.S. residents only.

Central Nervous System (CNS)

Eye Diseases

Immune System Diseases

Kidney Diseases

Nervous System Diseases

Immunovant

Thyroid Eye Disease

<p class="font_7">Immunovant’s investigational product candidate, IMVT-1401 (formerly known as RVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). We believe that this product has the potential to address a variety of IgG-mediated autoimmune diseases as a subcutaneous injection</p>

Batoclimab (IMVT-1401)

Myasthenia gravis

Batoclimab (IMVT-1401) 

Graves’ disease

Chronic inflammatory disorder

<p class="font_7">IMVT-1402, is also a novel, fully human FcRn-targeting antibody. As with batoclimab, in nonclinical studies, IMVT-1402 has been observed to reduce IgG antibody levels and is designed to enable a subcutaneous route of administration delivered in a matter of seconds.</p>

Immunovant

Company Details